Core Viewpoint - Caribou Biosciences, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its business operations and the viability of its product CB-010 during the specified class period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities between July 14, 2023, and July 16, 2024, with a deadline of February 24, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Caribou - The complaint claims that Caribou exaggerated the safety, effectiveness, and long-term viability of CB-010 compared to existing CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [3]. - It is alleged that Caribou faced significant risks regarding cash, liquidity, and capital necessary for ongoing business operations, including preclinical research related to its allogeneic CAR-NK platform [3]. - The issues raised in the complaint are expected to severely impact Caribou's business and operations, rendering the defendants' public statements materially false and misleading throughout the class period [3].
Caribou Biosciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 24, 2025 Deadline to file Lead Plaintiff Motion.